27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Epidemiological data show that both PD incidence rate and prevalence rate show a significant age-dependent growth trend [3]. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A new chaos-wavelet approach is presented for electroencephalogram (EEG)-based diagnosis of Alzheimer's disease (AD) employing a recently developed concept in graph theory, visibility graph (VG). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
After screening 3670 articles for eligibility, the review includes 12 studies. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Early detection of dementia is a key requirement for effective patient management. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Utilizing machine learning, we identify a 12-protein panel from cerebrospinal fluid proteomic datasets. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Assessing the mental status of patients with a neurobehavioral disorder is a critical element in the diagnosis and treatment of these patients. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia worldwide and is associated with substantial morbidity and mortality, including stroke, systemic embolism, heart failure, and dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The accurate diagnosis of Alzheimer's disease (AD) and its early stage, i.e., mild cognitive impairment, is essential for timely treatment and possible delay of AD. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Finally, the most relevant features are selected by means of the non-parametric Mann- Whitney U-test. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Significant predictive performance was observed for several neurocognitive disorders. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Utilizing clinical data, the highest ROC AUC scores attained were 0.989, 0.927, and 0.907 for the identification of the CN, MCI, and dementia stages, respectively. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The accurate diagnosis of Alzheimer's disease (AD) is essential for patient care and will be increasingly important as disease modifying agents become available, early in the course of the disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recently, there have been great interests for computer-aided diagnosis of Alzheimer's disease (AD) and its prodromal stage, mild cognitive impairment (MCI). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Computer Aided Diagnosis (CAD) constitutes an important tool for the early diagnosis of Alzheimer's Disease (AD), which, in turn, allows the application of treatments that can be simpler and more likely to be effective. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
INPH can be diagnosed accurately with CSF pressure monitoring and CSF drainage via a spinal catheter. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The Alzheimer's disease (AD) is recognized as one of the most common neurodegenerative causes of dementia worldwide, having been characterized by progressive cognitive decline for the most part. 2 key findings →
Participants: 461 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Three blood gene expression datasets of high dimensionality and low sample size (HDLSS) have been utilized in this study, with one dataset exhibiting significant class imbalance. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
It was found that the top cited 100 articles came from 51 journals and 31 countries. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Butyrylcholinesterase inhibition offers one of the formulated solutions to tackle the aggravating symptoms of dementia that downgrades to cholinergic neuronal loss in Alzheimer’s disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Research on AI's role in diagnosing neurological disorders is becoming widely recognized for its growing importance. 2 key findings →
Participants: 276 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Conventional dementia screening tools, whether paper tests or static artificial intelligence (AI) models, capture only a snapshot of cognition and need to be adminstered periodically. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The approval of disease-modifying treatments for Alzheimer's disease demands a rethinking of cognitive screening. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Participants reported routine screening for cognitive impairment only in the context of the Medicare annual wellness visit and generally avoided routine screening because of limited treatment options to support patients, such as poor access to geriatrics/neuropsychiatric services. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This approach predicts clinical progression (2-year Clinical Dementia Rating Sum of Boxes change > 1) with an area under the curve of 0.836. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is the waning of cognitive abilities, which is typically seen with the natural aging process and includes issues with memory, language, and problem-solving abilities. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →